Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04628481 · ClinicalTrials.gov registry record · Phase 2
A Study of Oral Ladarixin in Recent Onset Type 1 Diabetes and a Low Residual β-cell Function
A Phase 2 study, sponsored by Dompé Farmaceutici S.p.A.
- Terminated
- Registry status
- Phase 2
- Development phase
- 141
- Enrollment target
NCT04628481 is a Phase 2 study that was terminated before completion, run by Dompé Farmaceutici S.p.A. The registered enrollment target is 141 participants.
The verdict
NCT04628481, a Phase 2 study, was terminated before completion, sponsored by Dompé Farmaceutici S.p.A.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 141 participants
- Enrollment target
Study Summary
Objectives The objective of this clinical trial is to assess whether ladarixin treatment has an effect to preserve β-cell function and delay the progression of T1D in adolescent and adult patients. The safety of ladarixin in the specific clinical setting will be also evaluated.
Interventions
- DRUG Placebo
- DRUG Ladarixin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 141 participants |
| Start Date | 2021-01-12 |
| Est. Completion | 2025-10-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04628481
The ClinicalTrials.gov registry entry for NCT04628481 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 141 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dompé Farmaceutici S.p.A, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04628481 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04628481 about?
NCT04628481 is a clinical study titled "A Study of Oral Ladarixin in Recent Onset Type 1 Diabetes and a Low Residual β-cell Function". Objectives The objective of this clinical trial is to assess whether ladarixin treatment has an effect to preserve β-cell function and delay the progression of T1D in adolescent and adult patients. The safety of ladarixin in the specific clinical setting will be also evaluated.
What is the current status of trial NCT04628481?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 141 participants. The study started on 2021-01-12. Estimated completion is 2025-10-21.
What interventions are being tested in trial NCT04628481?
The interventions under investigation include: Placebo (DRUG), Ladarixin (DRUG).
Who is sponsoring clinical trial NCT04628481?
This trial is sponsored by Dompé Farmaceutici S.p.A, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.